ArticleCurrent medical science2026
Timing and Location are Keys: ERCP Success and Its Benefit in MPD Injury after Acute Pancreatitis.
Article in Current medical science, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
objectiveTranspapillary therapy remains a critical treatment modality for main pancreatic duct (MPD) injury after acute necrotizing pancreatitis. This study aimed to verify the factors linked to the technical success of transpapillary drainage by endoscopic retrograde cholangiopancreatography (ERCP) in managing MPD injury, and the impact of technical success on tube duration and overall survival.
methodsA retrospective analysis was conducted on patients who underwent ERCP for MPD injuries following acute pancreatitis from May 2019 to April 2021. Univariate and multivariate logistic regression analyses were employed to identify factors associated with successful treatment. Kaplan-Meier curves were used to analyze the impact of technical success on tube duration and overall survival.
resultsWe included 63 patients in whom MPD opacification was achieved (43 technical successes and 20 failures). The technical success group had a significantly higher proportion of patients whose interval from onset of acute pancreatitis to endoscopic transpapillary drainage (IOP) was less than 90 days (58.14%) than the failure group (20.00%, P = 0.005). Multivariate analysis revealed that an IOP < 90 days (OR = 0.24, 95% CI: 0.06-0.91, P = 0.036) and MPD injury located outside the head and neck of the pancreas (OR = 4.66, 95% CI: 1.10-19.77, P = 0.036) were independently associated with technical success. Technical success was associated with a shorter median tube indwelling time (10.3 months, 95% CI: 7.3-13.3) compared to technical failure (16.8 months, 95% CI: 12.3-21.3, P = 0.025).
conclusionsERCP should be performed within 90 days in patients with MPD injury, and the procedure has a higher success rate when the injury occurs outside the head and neck of the pancreas. This technical success significantly shortens drainage tube indwelling time and improves patients' quality of life.
Indexed as
Identifiers
42377888What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.